HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TRANSTHERA-B

10.310

-0.070-0.67%

Volume:4.54M

Turnover:46.60M

Market Cap:4.20B

PE:-11.63

High:10.440

Open:10.440

Low:10.120

Close:10.380

52wk High:679.500

52wk Low:9.010

Shares:407.00M

HK Float Shares:312.00M

Volume Ratio:0.52

T/O Rate:1.46%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.887

ROE:-62.88%

ROA:-32.06%

PB:8.64

PE(LYR):-11.63

PS:- -

Loading ...

Overview Company News Filings

TransThera Sciences names Sun Delong chief operating officer

Biotech Firm TRANSTHERA-B Conducts Third Heavily Discounted Share Placement in 2024, Raising $624M HKD in Total

TRANSTHERA-B Shares Surge Over 9% Following Completion of H Share Placement Raising Approximately HK$152 Million

TRANSTHERA-B Shares Surge Over 4% Following Release of Key Phase II Data for Tenegotinib at ASCO 2026

Movement Alert｜PharmJet AnKang-B Falls 5.41% in Regular Trading, Stock Under Pressure After ASCO Presentation of Key Phase II Clinical Data

TRANSTHERA-B Unveils Key Phase II Clinical Data for Tinengotinib in Advanced Cholangiocarcinoma at 2026 ASCO

HKEX's Tech 100 Index Undergoes Semi-Annual Rebalance: Seven New Entrants Including DEEPEXI TECH

TransThera Sciences Completes HK$157 Million Share Offering

MT Newswires Live

TransThera Completes HK$156.62 Million H-Share Placement, Enlarges Share Capital by 0.94%

Bulletin Express

TRANSTHERA-B Completes Placement of 3.836 Million Shares

TransThera Sciences places 3,836,000 new H shares at HK$ 40.83 each under general mandate

TransThera Sciences Gets China Approval for Cancer Study; to Partner with Shanghai Allist Pharma on Phase 2 Trial

MT Newswires Live

TRANSTHERA-B Shares Surge Over 8% on Approval of Phase II Trial for mCRPC Treatment

TransThera Sets 18 June 2026 Virtual AGM; Shareholders to Vote on FY 2025 Results, Auditor Renewal and Supervisory Committee Cancellation

Bulletin Express

TRANSTHERA-B Calls 18 June 2026 Virtual AGM; To Address 2025 Losses, No Dividend, Auditor Re-appointment and Governance Reshuffle

Bulletin Express

TransThera Sciences announces annual shareholder meeting

TRANSTHERA-B's Core Drug, Tinengotinib, Gains NMPA Approval for Phase II Trial in Advanced Prostate Cancer

TransThera says China NMPA clears Phase II trial of tinengotinib combo in advanced prostate cancer

TRANSTHERA-B Forges Clinical and Supply Partnership with Shanghai Allist Pharmaceuticals

Transthera Sciences (Nanjing) Inc - to Conduct Phase Ii Trial of Tt-973-MS and Firmonertinib in Advanced Nsclc

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/02617/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02617","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"TRANSTHERA-B","latestPrice":10.31,"timestamp":1787299687057,"preClose":10.38,"halted":0,"volume":4543800,"delay":0,"changeRate":-0.006743737957610817,"floatShares":312000000,"shares":407000000,"eps":-0.8868345239122081,"marketStatus":"Market Closed","change":-0.07,"latestTime":"08-21 16:08:07","open":10.44,"high":10.44,"low":10.12,"amount":46601191,"amplitude":0.030829,"askPrice":10.31,"askSize":5000,"bidPrice":10.3,"bidSize":10500,"shortable":3,"etf":0,"ttmEps":-0.8863140920731754,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":7,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":10.38,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":0.5223118835745755,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","floatShares":312000000,"roa":"-32.06%","roe":"-62.88%","lyrEps":-0.886835,"volumeRatio":0.5223118835745755,"shares":407000000,"dividePrice":0,"high":10.44,"amplitude":0.030829,"preClose":10.38,"low":10.12,"week52Low":9.01,"pbRate":"8.64","week52High":679.5,"institutionHeld":0,"latestPrice":10.31,"committee":0.354839,"eps":-0.8868345239122081,"divideRate":0,"volume":4543800,"delay":0,"ttmEps":-0.8863140920731754,"open":10.44,"prevYearClose":114.9,"prevWeekClose":10.33,"prevMonthClose":9.95,"prevQuarterClose":11.55,"fiveDayClose":10.33,"twentyDayClose":10.19,"sixtyDayClose":38.7,"earningDate":1787673600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02617\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"market":"HK","date":"2026-03-31","symbol":"02617","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774886400000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-25","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756085400000,"name":null,"time":"","dateTimestamp":1756051200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02617\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02617\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02617\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02617","date":"2026-08-21","current":-11.632445,"percent":0.95122,"low":-380.446233,"twenty":-208.418403,"median":-81.461274,"eighty":-38.522204,"high":-10.87103,"avg":-114.757849,"sd":96.187407,"marketCap":4205641106},"quantilePoints":[{"date":"2025-06-20","current":-17.403134,"twenty":-17.403134,"median":-17.403134,"eighty":-17.403134,"marketCap":5219203873},{"date":"2025-06-27","current":-36.622688,"twenty":-34.709071,"median":-32.493198,"eighty":-31.066553,"marketCap":11013909315},{"date":"2025-07-04","current":-44.802949,"twenty":-38.622694,"median":-35.660049,"eighty":-31.776499,"marketCap":13474674640},{"date":"2025-07-11","current":-39.630155,"twenty":-40.38446,"median":-38.336544,"eighty":-32.816725,"marketCap":11906928990},{"date":"2025-07-18","current":-43.957869,"twenty":-42.111612,"median":-39.630155,"eighty":-34.373739,"marketCap":13196846297},{"date":"2025-07-25","current":-49.067594,"twenty":-42.195906,"median":-40.285196,"eighty":-36.230637,"marketCap":14784436829},{"date":"2025-08-01","current":-50.963195,"twenty":-45.655878,"median":-41.371359,"eighty":-36.620356,"marketCap":15260713988},{"date":"2025-08-08","current":-58.015216,"twenty":-51.234741,"median":-42.017389,"eighty":-37.993773,"marketCap":17415868136},{"date":"2025-08-15","current":-66.867935,"twenty":-57.065221,"median":-42.261724,"eighty":-38.707864,"marketCap":20043330466},{"date":"2025-08-22","current":-72.723484,"twenty":-59.09189,"median":-43.957869,"eighty":-39.464263,"marketCap":21730145406},{"date":"2025-08-29","current":-49.610789,"twenty":-64.458089,"median":-47.896219,"eighty":-39.630155,"marketCap":21492006826},{"date":"2025-09-05","current":-57.867887,"twenty":-63.405379,"median":-50.300475,"eighty":-39.739866,"marketCap":25044240642},{"date":"2025-09-12","current":-176.221101,"twenty":-67.557018,"median":-51.642061,"eighty":-40.181616,"marketCap":76402794352},{"date":"2025-09-19","current":-137.321051,"twenty":-71.134174,"median":-54.042597,"eighty":-40.68225,"marketCap":59494955186},{"date":"2025-09-26","current":-219.814439,"twenty":-72.736767,"median":-55.62397,"eighty":-41.23574,"marketCap":56835741045},{"date":"2025-10-03","current":-208.418403,"twenty":-113.88308,"median":-57.213624,"eighty":-41.375772,"marketCap":54017767851},{"date":"2025-10-10","current":-183.264838,"twenty":-172.633767,"median":-57.790453,"eighty":-41.583173,"marketCap":47429267143},{"date":"2025-10-17","current":-311.562728,"twenty":-178.967921,"median":-58.015216,"eighty":-41.927636,"marketCap":80570219499},{"date":"2025-10-24","current":-293.038662,"twenty":-206.454369,"median":-63.574223,"eighty":-42.029097,"marketCap":75807447903},{"date":"2025-10-31","current":-281.572204,"twenty":-212.338922,"median":-65.741367,"eighty":-42.067733,"marketCap":72949784945},{"date":"2025-11-07","current":-338.772318,"twenty":-240.199465,"median":-68.232426,"eighty":-42.195906,"marketCap":87714376893},{"date":"2025-11-14","current":-312.135011,"twenty":-262.893893,"median":-70.289151,"eighty":-42.482614,"marketCap":81046496658},{"date":"2025-11-21","current":-312.892206,"twenty":-281.392507,"median":-71.392356,"eighty":-43.133487,"marketCap":81205255711},{"date":"2025-11-28","current":-305.66478,"twenty":-292.6573,"median":-72.756691,"eighty":-44.126885,"marketCap":79617665179},{"date":"2025-12-05","current":-292.058382,"twenty":-294.387608,"median":-99.507708,"eighty":-45.187328,"marketCap":76204345536},{"date":"2025-12-12","current":-243.995471,"twenty":-293.167092,"median":-152.573856,"eighty":-47.193393,"marketCap":63781449623},{"date":"2025-12-19","current":-248.269013,"twenty":-292.997062,"median":-174.177612,"eighty":-49.176233,"marketCap":65051522048},{"date":"2025-12-24","current":-196.609225,"twenty":-292.87226,"median":-176.029803,"eighty":-49.50215,"marketCap":51676071816},{"date":"2026-01-02","current":-170.268162,"twenty":-292.367293,"median":-176.029803,"eighty":-50.024601,"marketCap":44928812055},{"date":"2026-01-09","current":-172.395935,"twenty":-291.502465,"median":-173.687618,"eighty":-50.606284,"marketCap":45603538031},{"date":"2026-01-16","current":-142.824051,"twenty":-290.689477,"median":-172.622298,"eighty":-50.90198,"marketCap":37903723951},{"date":"2026-01-23","current":-125.658859,"twenty":-289.035292,"median":-170.268162,"eighty":-51.777834,"marketCap":33316302355},{"date":"2026-01-30","current":-123.813683,"twenty":-286.862177,"median":-169.566856,"eighty":-52.840115,"marketCap":32977154367},{"date":"2026-02-06","current":-105.494623,"twenty":-283.350344,"median":-167.82666,"eighty":-53.700055,"marketCap":28169232889},{"date":"2026-02-13","current":-102.143547,"twenty":-281.033113,"median":-142.637109,"eighty":-54.549461,"marketCap":27431087268},{"date":"2026-02-20","current":-99.091969,"twenty":-280.673719,"median":-140.820404,"eighty":-54.88737,"marketCap":26573242357},{"date":"2026-02-27","current":-101.401985,"twenty":-277.873293,"median":-135.446139,"eighty":-55.077905,"marketCap":27490936913},{"date":"2026-03-06","current":-136.499284,"twenty":-268.489172,"median":-127.818396,"eighty":-56.170035,"marketCap":36707782236},{"date":"2026-03-13","current":-113.20329,"twenty":-265.946326,"median":-125.658859,"eighty":-56.966285,"marketCap":30583168569},{"date":"2026-03-20","current":-101.699451,"twenty":-264.885138,"median":-122.419285,"eighty":-57.460964,"marketCap":27371237623},{"date":"2026-03-27","current":-103.891016,"twenty":-259.5894,"median":-118.720319,"eighty":-57.713018,"marketCap":27889934546},{"date":"2026-04-02","current":-103.689961,"twenty":-256.279611,"median":-116.735022,"eighty":-57.836913,"marketCap":27969734073},{"date":"2026-04-10","current":-80.663784,"twenty":-255.242863,"median":-113.754326,"eighty":-57.879207,"marketCap":27371237623},{"date":"2026-04-17","current":-81.335146,"twenty":-254.749157,"median":-113.20329,"eighty":-57.943799,"marketCap":27610636203},{"date":"2026-04-24","current":-69.75013,"twenty":-253.791099,"median":-110.250158,"eighty":-58.025793,"marketCap":23679242293},{"date":"2026-04-30","current":-61.379887,"twenty":-252.626844,"median":-107.193308,"eighty":-58.709304,"marketCap":20850663862},{"date":"2026-05-08","current":-65.459145,"twenty":-251.564027,"median":-106.48355,"eighty":-58.020504,"marketCap":22305361341},{"date":"2026-05-15","current":-57.457667,"twenty":-249.188687,"median":-106.083059,"eighty":-57.919993,"marketCap":19630334311},{"date":"2026-05-22","current":-50.784784,"twenty":-247.674355,"median":-104.198267,"eighty":-57.649604,"marketCap":17310899997},{"date":"2026-05-29","current":-41.763424,"twenty":-245.295721,"median":-103.852131,"eighty":-57.457667,"marketCap":14285310527},{"date":"2026-06-05","current":-37.606441,"twenty":-243.995471,"median":-103.234551,"eighty":-55.321243,"marketCap":12882070430},{"date":"2026-06-12","current":-38.299212,"twenty":-239.592317,"median":-102.28828,"eighty":-53.347698,"marketCap":13110504864},{"date":"2026-06-18","current":-33.64261,"twenty":-235.649979,"median":-102.143547,"eighty":-51.161877,"marketCap":11544097313},{"date":"2026-06-26","current":-10.87103,"twenty":-223.802745,"median":-101.125662,"eighty":-50.162538,"marketCap":3712059560},{"date":"2026-07-03","current":-14.085963,"twenty":-220.323597,"median":-100.505297,"eighty":-47.51031,"marketCap":4813439869},{"date":"2026-07-10","current":-12.489761,"twenty":-217.694001,"median":-99.314488,"eighty":-43.652943,"marketCap":4262749714},{"date":"2026-07-17","current":-11.456979,"twenty":-215.893769,"median":-98.774546,"eighty":-42.55123,"marketCap":3924177249},{"date":"2026-07-24","current":-12.133097,"twenty":-213.808047,"median":-93.131819,"eighty":-41.957553,"marketCap":4156690870},{"date":"2026-07-31","current":-11.824868,"twenty":-212.088453,"median":-87.290837,"eighty":-41.541423,"marketCap":4058790398},{"date":"2026-08-07","current":-13.332054,"twenty":-210.416628,"median":-83.155604,"eighty":-40.356892,"marketCap":4585005434},{"date":"2026-08-14","current":-12.237188,"twenty":-208.788963,"median":-82.408413,"eighty":-39.630155,"marketCap":4213799478},{"date":"2026-08-21","current":-12.186563,"twenty":-208.418403,"median":-81.461274,"eighty":-38.522204,"marketCap":4205641106}],"updateTime":1787481598284},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02617\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2642955742","title":"TransThera Sciences names Sun Delong chief operating officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2642955742","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642955742?lang=en_us&edition=fundamental","pubTime":"2026-06-12 21:21","pubTimestamp":1781270500,"startTime":"0","endTime":"0","summary":"Transthera Sciences  named Sun Delong chief operating officer, effective June 12, 2026.Earlier roles included deputy general manager at Liaoning Herbpex Pharmaceutical Group, national sales head at Jiangsu Simcere Pharmaceutical.Holds a bachelor’s degree in pharmacy from Shenyang Pharmaceutical University.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL7dxm29:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02096","BK1191","BK1583","BK1606","02186","WHIB","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155616891","title":"Biotech Firm TRANSTHERA-B Conducts Third Heavily Discounted Share Placement in 2024, Raising $624M HKD in Total","url":"https://stock-news.laohu8.com/highlight/detail?id=1155616891","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155616891?lang=en_us&edition=fundamental","pubTime":"2026-06-12 11:21","pubTimestamp":1781234482,"startTime":"0","endTime":"0","summary":"The biotech company TRANSTHERA-B (02617.HK), listed under the Hong Kong exchange's Chapter 18A rules, has once again tapped the capital markets.On May 27, 2024, the company announced it had placed...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134400927","title":"TRANSTHERA-B Shares Surge Over 9% Following Completion of H Share Placement Raising Approximately HK$152 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1134400927","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134400927?lang=en_us&edition=fundamental","pubTime":"2026-06-08 10:10","pubTimestamp":1780884651,"startTime":"0","endTime":"0","summary":"Shares of TRANSTHERA-B (02617) surged by more than 14% during the trading session. At the time of writing, the stock is up 8.87%, trading at HK$34.38. Recently, TRANSTHERA-B (02617) announced the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157870740","title":"TRANSTHERA-B Shares Surge Over 4% Following Release of Key Phase II Data for Tenegotinib at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1157870740","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157870740?lang=en_us&edition=fundamental","pubTime":"2026-06-08 09:55","pubTimestamp":1780883744,"startTime":"0","endTime":"0","summary":"Shares of TRANSTHERA-B (ASX: 02617) have risen by more than 4%. At the time of writing, the stock is up 4.05% to HK$32.74, with a trading volume of HK$45.26 million.The recent price movement follows...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4585","02617","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142379650","title":"Movement Alert｜PharmJet AnKang-B Falls 5.41% in Regular Trading, Stock Under Pressure After ASCO Presentation of Key Phase II Clinical Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1142379650","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142379650?lang=en_us&edition=fundamental","pubTime":"2026-06-05 15:22","pubTimestamp":1780644135,"startTime":"0","endTime":"0","summary":"On June 5, PharmJet AnKang-B (Yaojie Ankang-B) declined 5.41% in regular trading, trading at HK$32.14 per share, with trading volume of approximately HK$73.33 million.On the news front, the company...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126409720","title":"TRANSTHERA-B Unveils Key Phase II Clinical Data for Tinengotinib in Advanced Cholangiocarcinoma at 2026 ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=1126409720","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126409720?lang=en_us&edition=fundamental","pubTime":"2026-05-31 18:10","pubTimestamp":1780222228,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) has announced the presentation of its latest research findings for its core product, tinengotinib, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108594441","title":"HKEX's Tech 100 Index Undergoes Semi-Annual Rebalance: Seven New Entrants Including DEEPEXI TECH","url":"https://stock-news.laohu8.com/highlight/detail?id=1108594441","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108594441?lang=en_us&edition=fundamental","pubTime":"2026-05-29 19:15","pubTimestamp":1780053358,"startTime":"0","endTime":"0","summary":"On May 29, Hong Kong Exchanges and Clearing Limited (HKEX) announced the results of the semi-annual review for the HKEX Tech 100 Index. The index will add seven technology stocks: DEEPEXI TECH...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","LU0630378692.HKD","LU0762542818.HKD","LU0886674414.USD","BK1183","LU1366334578.USD","LU0048597586.USD","SG9999004220.SGD","LU0274383008.USD","SG9999002463.SGD","02590","LU0516423174.USD","LU1282649067.USD","LU0011963245.USD","LU0540923850.HKD","LU0117841782.USD","01384","BK1589","LU0708995583.HKD","LU1481107354.HKD","LU0084288322.USD","LU0359201885.HKD","LU1993786604.SGD","HKXCY","LU0762540952.USD","LU0819121731.USD","01729","LU1051769294.HKD","LU0501845795.SGD","LU1813983027.USD","BK1116","LU2257852520.SGD","LU0955669360.SGD","LU1981816686.USD","LU0955648018.USD","LU0370786039.SGD","LU1242518857.USD","LU1048588211.SGD","80388","LU0516422952.EUR","LU0106959298.USD","LU0384037296.USD","LU0314109678.HKD","LU0327786744.USD","IE00BZ08YR35.GBP","LU0561508036.HKD","LU0348827113.USD","LU0072462343.USD","LU0320764599.SGD","LU0577902611.USD","LU0898667661.SGD","LU1051768304.USD","LU1044874839.SGD","LU0082770016.SGD","LU0588546209.SGD","LU0140636845.USD","SG9999001051.SGD","02643","LU1282649810.SGD","LU0348825331.USD","LU0577902538.SGD","LU0594300419.USD","LU0620787316.HKD","LU0048580855.USD","LU0651946864.USD","BK1610","LU0831103253.SGD","BK1521","BK1255","BK1149","LU2039709279.SGD","LU1023057109.AUD","LU0918141705.HKD","LU0210527791.USD","LU0784639295.USD","BK1144","LU0197773160.USD","LU0417516902.SGD","LU0197773673.USD","LU0577902454.USD","BK1161","LU0648948544.HKD","LU1504937902.USD","BK1506","LU1130305938.SGD","LU1242518931.SGD","LU0169518387.USD","LU0634319403.HKD","LU2449936058.SGD","LU0061477393.USD","LU0149534421.HKD","02617","BK1131","BK1523","LU0348766576.USD","LU0979878070.USD","LU0348767384.USD","LU0577902298.EUR","IE0003851619.USD","LU0117844026.USD","LU0096374516.USD","LU0149721374.USD","LU0577902371.SGD","LU0873338254.USD","LU0348735423.USD","LU1226287529.USD","LU0516422440.USD","SG9999002562.SGD","LU1807302812.USD","BK1117","LU1282648689.USD","LU0572944931.SGD","LU0630378429.USD","06869","LU0359202008.SGD","LU0831093199.SGD","LU1044876610.USD","LU0918141887.USD","LU0164880469.USD","HK0000151867.HKD","LU0417516738.SGD","IE00B3T34201.USD","LU0955623706.USD","LU0072913022.USD","LU1655091459.SGD","00388","LU1734074674.USD","LU0607220059.USD","LU0307460666.USD","LU0516423091.SGD","LU0605514214.HKD","LU0762541174.USD","LU0456846285.SGD","LU1044875133.USD","LU1048596156.SGD","LU1642822792.SGD","IE0003795394.USD","LU2226246903.HKD","02525","HK0000107257.USD","LU0797268264.HKD","LU1366334651.USD","LU1105468828.SGD","LU0082770016.USD","LU0165289439.USD","LU0251144936.SGD","IE00BKZH1Z71.USD","LU1282649141.HKD","IE00BZ08YT58.USD","LU0348816934.USD","LU0791591158.USD","LU1831875114.USD","SG9999001846.SGD","SG9999006597.SGD","601869","LU0043850808.USD","LU0791590937.USD","LU0651947912.USD","SG9999001093.SGD","LU0164939612.USD","LU0211977185.USD","LU0516422366.SGD","SGXZ90724238.SGD","LU0650527681.SGD","LU0821914370.USD","LU0067412154.USD","LU0488056044.USD","LU0594300179.USD","LU0261947096.USD","LU0052750758.USD","LU1211504680.USD","LU0856984785.SGD","LU0348814723.USD","LU0359201612.USD","LU0819123356.HKD","HSAI","LU1328277881.USD","LU1515016050.SGD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638512654","title":"TransThera Sciences Completes HK$157 Million Share Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2638512654","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638512654?lang=en_us&edition=fundamental","pubTime":"2026-05-28 12:56","pubTimestamp":1779944187,"startTime":"0","endTime":"0","summary":"TransThera Sciences   said it completed a HK$156.6 million share offering, according to a Wednesday filing with the Hong Kong bourse.The drugmaker's shares fell over 5% in late morning trade Thursday.The company sold 3.8 million shares priced at HK$40.83 each to raise funds for the development of new indications for its core product, tinengotinib.The shares represent 1.23% of the company's existing H shares and 0.94% of its enlarged share capital.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182101486","title":"TransThera Completes HK$156.62 Million H-Share Placement, Enlarges Share Capital by 0.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=1182101486","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182101486?lang=en_us&edition=fundamental","pubTime":"2026-05-27 21:02","pubTimestamp":1779886972,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (TransThera) has finalised the placement of 3.84 million new H shares at HK$40.83 each, generating gross proceeds of HK$156.62 million. Net of fees and expenses,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184062559","title":"TRANSTHERA-B Completes Placement of 3.836 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1184062559","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184062559?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:58","pubTimestamp":1779886734,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) has announced that all conditions under the placement agreement have been fulfilled, and the placement was completed on May 27, 2026. The placing agent successfully placed a total of 3.836 million shares to no fewer than six placees at a placing price of HK$40.83 per share.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638688216","title":"TransThera Sciences places 3,836,000 new H shares at HK$ 40.83 each under general mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=2638688216","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638688216?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:55","pubTimestamp":1779886533,"startTime":"0","endTime":"0","summary":"Transthera Sciences  completed a placement of 3,836,000 new H shares at HK$ 40.83 per share on May 27, 2026.Gross proceeds totaled HK$ 156.62 million; net proceeds were HK$ 152.13 million, implying a net issue price of HK$ 39.66.Net proceeds earmarked 90% for Tinengotinib new-indication development; 10% for working capital and general corporate purposes.Placed to at least six investors; none became a substantial shareholder immediately following completion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on May 27, 2026, and is solely responsible for the informati","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL2Lt9qs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638579576","title":"TransThera Sciences Gets China Approval for Cancer Study; to Partner with Shanghai Allist Pharma on Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2638579576","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638579576?lang=en_us&edition=fundamental","pubTime":"2026-05-27 13:54","pubTimestamp":1779861286,"startTime":"0","endTime":"0","summary":"TransThera Sciences   said Chinese regulators approved its phase 2 clinical trial of tinengotinib to treat prostate cancer, according to a Tuesday filing with the Hong Kong bourse.The company's shares fell over 3% in afternoon trade Wednesday.The firm will evaluate a combination of tinengotinib and novel hormone therapy in an open-label study in subjects with metastatic castration-resistant prostate cancer.In a separate announcement, the firm said it is partnering with Shanghai Allist Pharmaceuticals on another open-label phase 2 study to evaluate TT-00973-MS tablets in combination with firmonertinib mesylate tablets in patients with locally advanced or metastatic non-small cell lung cancer.Based on the results of the study, the parties may collaborate on a phase 3 study.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133717342","title":"TRANSTHERA-B Shares Surge Over 8% on Approval of Phase II Trial for mCRPC Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1133717342","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133717342?lang=en_us&edition=fundamental","pubTime":"2026-05-27 09:34","pubTimestamp":1779845680,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) opened higher by more than 8%. As of the time of writing, the stock is up 8.12% to HK$43.92, with a turnover of HK$2.1082 million. On the news front, on May 26, TRANSTHERA-B...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","02617","BK4585","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166846465","title":"TransThera Sets 18 June 2026 Virtual AGM; Shareholders to Vote on FY 2025 Results, Auditor Renewal and Supervisory Committee Cancellation","url":"https://stock-news.laohu8.com/highlight/detail?id=1166846465","media":"Bulletin Express","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166846465?lang=en_us&edition=fundamental","pubTime":"2026-05-26 23:43","pubTimestamp":1779810224,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (“TransThera-B”) has convened its 2025 annual general meeting (AGM) for 10:30 a.m. on 18 June 2026. The meeting will be held entirely online via the Vistra eVoting...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126809826","title":"TRANSTHERA-B Calls 18 June 2026 Virtual AGM; To Address 2025 Losses, No Dividend, Auditor Re-appointment and Governance Reshuffle","url":"https://stock-news.laohu8.com/highlight/detail?id=1126809826","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126809826?lang=en_us&edition=fundamental","pubTime":"2026-05-26 23:06","pubTimestamp":1779808019,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (TransThera Sciences (Nanjing), Inc.) has scheduled its 2026 Annual General Meeting (AGM) for 18 June 2026 at 10:30 a.m. via the Vistra eVoting Portal. Key items on the agenda include: •...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638545673","title":"TransThera Sciences announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2638545673","media":"Reuters","labels":["conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638545673?lang=en_us&edition=fundamental","pubTime":"2026-05-26 23:06","pubTimestamp":1779807964,"startTime":"0","endTime":"0","summary":"Transthera Sciences  will hold its annual general meeting as a virtual meeting on June 18, 2026.Shareholders will vote on the 2025 board report, supervisory committee report, audited consolidated financial statements, annual report, profit distribution plan, and uncovered losses.Items also include reappointing Ernst & Young as 2026 auditor, setting 2026 pay plans for directors and supervisors, and appointing Feng Weibo as an independent director.Special resolutions cover mandates to issue shares, repurchase H shares, extend the issuance mandate by shares repurchased, and cancel the supervisory committee.Proposals also include changes to the business scope, amendments to the articles of association, and updates to related appendices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interprete","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL3FDR9V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1615","BK1095","BK1161","09898"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139428390","title":"TRANSTHERA-B's Core Drug, Tinengotinib, Gains NMPA Approval for Phase II Trial in Advanced Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1139428390","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139428390?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:42","pubTimestamp":1779802941,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that its core product, Tinengotinib (TT00420), in combination with novel hormonal therapy (NHT) for the treatment of metastatic castration-resistant prostate cancer...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638510954","title":"TransThera says China NMPA clears Phase II trial of tinengotinib combo in advanced prostate cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2638510954","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638510954?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:38","pubTimestamp":1779802730,"startTime":"0","endTime":"0","summary":"Transthera Sciences won China NMPA clearance on May 25, 2026 to start a Phase II trial of tinengotinib with novel hormone therapy in mCRPC.Study targets patients whose metastatic castration-resistant prostate cancer progressed on prior treatments; trial will assess safety, efficacy, pharmacokinetics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on May 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL48My5P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150771470","title":"TRANSTHERA-B Forges Clinical and Supply Partnership with Shanghai Allist Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=1150771470","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150771470?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:38","pubTimestamp":1779802707,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) has announced a clinical collaboration and drug supply agreement with Shanghai Allist Pharmaceuticals Co.,Ltd. (Shanghai Allist Pharmaceuticals). The two companies will jointly...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617","688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638751032","title":"Transthera Sciences (Nanjing) Inc - to Conduct Phase Ii Trial of Tt-973-MS and Firmonertinib in Advanced Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2638751032","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638751032?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:28","pubTimestamp":1779802135,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nFWN4230IV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":4,"totalSize":140,"code":"91000000","status":"200"}]}}